Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4 Study to Evaluate Nasopharyngeal SARS-CoV-2 Viral Shedding After Halodine Nasal Antiseptic in Patients With COVID-19

NCT04517188 is registered in ClinicalTrials.gov with Halodine LLC as lead sponsor.

NCT NCT04517188
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04517188 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4 Study to Evaluate Nasopharyngeal SARS-CoV-2 Viral Shedding After Halodine Nasal Antiseptic in Patients With COVID-19
Lead sponsor
Halodine LLC
Phase
Phase 4
Overall status
Unknown status
Start date
April 1, 2021
Completion date
July 1, 2021
Enrollment
40 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2 infection